Robert Ward

Robert Ward

President and Chief Executive Officer

Bob Ward joined Radius Health as president and chief executive officer in 2013. Bob has more than 25 years of experience in the biopharmaceutical industry on both the R&D and the business side of a number of leading companies. During his tenure, Radius Health has completed late stage development of its lead compound and filed the first global regulatory new drug applications, successfully raised over $750 million in private and public financings – including an initial public offering in 2014, and advanced other novel compounds/drug delivery technologies in clinical development. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca (AZ) focusing on areas outside of AZ's historical therapeutic focus, including orphan drugs and endocrinology. After starting his career in the Molecular Biology discovery group at Genentech, Mr. Ward progressed through a series of management and executive roles with established biopharmaceutical companies including NPS Pharmaceuticals, Schering-Plough (Merck), and Bristol-Myers Squibb. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara; an M.S. in Management from the New Jersey Institute of Technology; and an M.A. in Immunology from The Johns Hopkins University School of Medicine.

Lorraine Fitzpatrick, M.D.

Lorraine Fitzpatrick, M.D.

Chief Medical Officer

Lorraine Fitzpatrick, M.D., has served as our Chief Medical Officer since July 2015. Prior to joining Radius, Dr. Fitzpatrick was a Medicine Development Leader and Group Director at GlaxoSmithKline, a pharmaceutical company, from August 2006 to July 2015. Prior to GlaxoSmithKline, she was an Executive Director at Amgen Inc., a biopharmaceutical company, focusing on osteoporosis and oncology from 2004 to 2006. She has served as Chair of the General Clinical Research Center study section of the National Center for Research Resources, National Institute of Health, or NIH; on the Advocacy Committee of the American Society of Bone and Mineral Research, or ASBMR; and as Chair of the Public Communications Committee and the Media Relations Steering Committee of The Endocrine Society, TES. She has also been a member of the Publications Committee of the ASBMR and TES and on the Advisory Committee for the Office of Research on Women's Health at the NIH. Dr. Fitzpatrick has served on the National Committee for Quality Assurance Technical Subgroup on Osteoporosis, the Clinical Guidelines Committee of TES, the Scientific Program Committees of North American Menopause Society and the ASBMR, and as Associate Editor for The Mayo Clinic Proceedings and the American Medical Association Scientific Advisory Board: Osteoporosis Guidelines. Dr. Fitzpatrick received a B.S. in Molecular Biology from Wellesley College and received her medical degree from the Pritzker School of Medicine at the University of Chicago.

Nick Harvey

Nick Harvey

Senior Vice President, Chief Financial Officer

Nick Harvey has served as our Senior Vice President, Chief Financial Officer, Treasurer and Secretary since November 2010, and served as a member of our Board of Directors from November 2010 until the consummation of the merger of our predecessor company with us in May 2011, or the Merger. Prior to that, Mr. Harvey served as the Chief Financial Officer and Senior Vice President of our predecessor company from December 2006 until the Merger. Mr. Harvey received a Bachelor of Economics degree and a Bachelor of Laws degree with first-class honors from the Australian National University and an M.B.A. from the Harvard Business School.

Gary Hattersley, PhD

Gary Hattersley, PhD

Chief Scientific Officer

Gary Hattersley, Ph.D., served as Chief Scientific Officer since January 2014. Prior to his current role, Dr. Hattersley served as our Senior Vice President of Preclinical Development from December 2011 to December 2013, and President of Biology from May 2011 to December 2011. From 2003 until the Merger, Dr. Hattersley served in various roles in our predecessor company, including as Vice President of Biology, Senior Director of Research and Director of Disease Biology & Pharmacology. Dr. Hattersley received a Ph.D. in Experimental Pathology from St. George's Hospital Medical School.

Brent Hatzis-Schoch J.D.

Brent Hatzis-Schoch J.D.

Senior Vice President and General Counsel

Brent Hatzis-Schoch J.D. has served as our Senior Vice President, General Counsel, since April 2015. Prior to joining Radius, from July 2013 to April 2015. Mr. Hatzis-Schoch was Senior Vice President and Chief Legal Counsel of Merz Pharma in Frankfurt, Germany. Prior to Merz, Mr. Hatzis-Schoch served for five years as General Counsel to Agennix AG, a publicly-traded development stage biopharmaceutical company. He has held senior legal positions in the U.S. and internationally, including as European legal counsel for Baxter International, Associate General Counsel of Pharmacia Corporation, and General Counsel of GPC Biotech AG. Mr. Hatzis-Schoch holds a J.D. from George Washington University and a B.A. from the University of Delaware.

Dinesh Purandare

Dinesh Purandare

Senior Vice President, Global Oncology and VMS

Dinesh Purandare has served as our Senior Vice President, Global Oncology and VMS since March 2015. Prior to joining Radius, Mr. Purandare spent five years at Sanofi Oncology, a pharmaceutical company. He held the role of Vice President and Head of Marketing from March 2010 to September 2012, and Vice President and Project Head, from October 2012 to March 2015. He also co-chaired the Joint Development Committee (Oncology) of Sanofi and Regeneron Pharmaceuticals and was a member of the Oncology Management Team at Sanofi. Prior to Sanofi, he served as Vice President and Head of Oncology Center of Excellence at GlaxoSmithKline headquarters in the UK and held other senior positions at Pharmacia /Pfizer and Farmitalia Carlo Erba (Milan, Italy). Mr. Purandare received degrees in Business Management and Organic Chemistry from the University of Bombay. He also received a Diploma in Advanced Marketing Management from the Chartered Institute of Marketing, U.K.

David P. Snow

David P. Snow

Chief Commercial Officer

David Snow has served as our Chief Commercial Officer since September 2015. Prior to joining Radius, Mr. Snow was President of the biopharmaceutical company, AstraZeneca's China business from January 2012 to December 2014. He was also the first global commercialization Vice President for AstraZeneca's prescription medication Brilinta and head of U.S. Commercial Operations from March 2010 to December 2011. Before joining AstraZeneca, Mr. Snow held numerous global and US commercial leadership roles for Bristol-Myers Squibb, Searle and Hoechst-Roussel. He served on the Research and Development based Pharmaceutical Association Committee industry association board in China for several years. Mr. Snow received his B.S. in Business Administration from Auburn University, and an M.B.A from New York University—Leonard N. Stern School of Business.

Greg Williams, PhD, MBA

Greg Williams, PhD, MBA

Chief Development Officer

Gregory Williams, Ph.D., has served as our Chief Development Officer since January 2014. Prior to joining Radius, Dr. Williams was Vice President of Regulatory Affairs, Global Product and Clinical Development, and Program Management with The Medicines Company, a biopharmaceutical company, from 2006 to 2013. He was Vice President of Regulatory Affairs, Regulatory Compliance and Program Management for NPS Pharmaceuticals, a pharmaceutical company, from 2004 to 2006. Dr. Williams has a Ph.D. in Biopharmaceutics from Rutgers University and an M.B.A. from Cornell University.

Kurt C. Graves

Kurt C. Graves has served on our Board of Directors since May 2011 and as Chairman of our Board of Directors since November 2011. Mr. Graves has been the Chairman, President and Chief Executive Officer of Intarcia Therapeutics, a biotechnology company, since April 2012. Mr. Graves served as Executive Chairman of Biolex Therapeutics, a biotechnology company, from November 2010 to March 2012, and served as Executive Chairman of Intarcia Therapeutics from August 2010 to April 2012. Previously, he served as Executive Vice President, Chief Commercial Officer and Head of Strategic Development at Vertex Pharmaceuticals Inc. from July 2007 to October 2009. Prior to joining Vertex, Mr. Graves held various leadership positions at Novartis pharmaceuticals from 1999 to June 2007. He was also the first Chief Marketing Officer for the Pharmaceuticals division from September 2003 to June 2007. He currently serves as a director of Intarcia Therapeutics, Seres Therapeutics and Achillion Pharmaceuticals. He served on the board of directors of Biolex Therapeutics and Springleaf Therapeutics from 2010 to 2012. Mr. Graves received a B.S. in Biology from Hillsdale College. We believe Mr. Graves is qualified to serve as a member of our Board of Directors because of his extensive experience in the life sciences industry, membership on various boards of directors and his leadership and management experience.

Alan H. Auerbach

Alan H. Auerbach has served on our Board of Directors since May 2011 and served as a member of the Board of Directors of our predecessor company from October 2010 until the Merger. Mr. Auerbach is currently the Founder, Chief Executive Officer, President and Chairman of the Board of Puma Biotechnology, Inc., a company dedicated to in-licensing and developing drugs for the treatment of cancer and founded in 2010. Previously, Mr. Auerbach founded Cougar Biotechnology, or Cougar, in May 2003 and served as the company's Chief Executive Officer, President and as a member of its Board of Directors until July 2009. From July 2009 until January 2010, Mr. Auerbach served as the Co-Chairman of the Integration Steering Committee at Cougar after its acquisition by Johnson & Johnson. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. We believe Mr. Auerbach is qualified to serve as a member of our Board of Directors because of his business and professional experience, including his leadership of Cougar in drug development, private and public financings and a successful sale of the business.

Willard H. Dere M.D

Willard H. Dere, M.D. has served on our Board of Directors since November 2014. Dr. Dere has been Executive Director of Personalized Health at the University of Utah Health Sciences Center, and a Professor of Medicine in the School of Medicine since November 2014. Prior to that, he served at Amgen Inc., a biopharmaceutical company, as the Senior Vice President, Global Development from December 2004 to June 2007, and from April 2014 to October 2014, and as International Chief Medical Officer from January 2007 to April 2014. Before he joined Amgen in 2003, Dr. Dere served as Vice President of Endocrine, Bone and General Medicine Research and Development at Eli Lilly and Company, a biopharmaceutical company, where he also held various other roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. Dr. Dere received B.A. degrees in history and zoology and a M.D. degree from the University of California, Davis. We believe Mr. Dere is qualified to serve as a member of our Board of Directors because of his strong medical background and extensive experience in the pharmaceutical industry.

Catherine Friedman

Catherine Friedman has served on our Board of Directors since August 2015. Previously, Ms. Friedman held the position of Managing Director at Morgan Stanley from 1997 to 2006 and head of West Coast Healthcare and co-head of the Biotechnology Practice at Morgan Stanley from 1993 to 2006. Since 2007, Ms. Friedman has been a director of XenoPort Inc., where she serves on the Audit and Nominating and Governance Committees, and Enteromedics, where she serves as Chair of the Audit Committee; in June 2014, she joined the Board of Innoviva (formerly known as Theravance), where she serves on the Audit and Compensation Committees; and in May 2013 she joined the Board of GSV Capital, a publicly traded investment fund, where she serves as Chair of the Audit Committee and on the Valuation Committee. Ms. Friedman is a member of the Board of Trustees for Sacred Heart Schools in Atherton. She is a graduate of Harvard University and received an MBA from the University of Virginia Darden School of Business, where she is currently a Darden School Foundation Board of Trustees member. We believe Ms. Friedman is qualified to serve as a member of our Board of Directors due to her extensive experience as a member on various boards of directors, her educational background and her previous leadership and management roles.

Ansbert K. Gadicke, MD

Ansbert K. Gadicke, M.D. has served on our Board of Directors since May 2011 and served as a member of the board of directors of our predecessor company from November 2003 until the Merger. Dr. Gadicke has been the Co-Founder and Managing Director of MPM Capital, a venture capital firm, since August 1996. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. Dr. Gadicke is a director of Chiasma, Inc., OSS Healthcare, Inc., Sideris Pharmaceuticals, Inc., RWHD, Inc. and Mitokyne, Inc. He served on the board of directors of Idenix Pharmaceuticals, Inc. from 1998 to 2005, BioMarin Pharmaceuticals, Inc. from 1997 to 2001, Verastem, Inc. from 2010 to 2012, Pharmasset, Inc. from 1999 to 2007 and PharmAthene, Inc. from 2004 to 2007. We believe Dr. Gadicke is qualified to serve as a member of our Board of Directors because of his business and professional experience, including his experience in the venture capital industry and his years of analyzing development opportunities in the life sciences sector.

Jean-Pierre Garnier

Dr. Garnier Ph.D. is currently Chairman of the Board of Actelion Ltd., and was previously Chief Executive Officer of GlaxoSmithKline plc. In addition, Dr. Garnier is also a member of the Board of Directors of United Technologies Corporation and of Renault S.A., and an Operating Partner at Advent International. Dr. Garnier previously served as Chief Executive Officer of Pierre Fabre S.A. from 2008 to 2010 and as Chief Executive Officer and Executive Member of the Board of Directors of GlaxoSmithKline plc from 2000 to 2008. Dr. Garnier served as Chief Executive Officer of SmithKline Beecham plc in 2000 and as Chief Operating Officer and Executive Member of the Board of Directors of SmithKline Beecham plc from 1996 to 2000. In 2009, he was made a Knight Commander of the British Empire. In 2007, he was promoted from Chevalier to Officier de la Légion d'Honneur of France. In 2006, he was named to the global list of top 20 CEOs by the Best Practice Institute. Dr. Garnier was previously Chairman of Cerenis from 2010 to 2011, and a board member of the Stanford Advisory Council on Interdisciplinary Biosciences, Weill Cornell Medical College and the Dubai International Capital Advisory Board. He is a member of the Advisory Board of the Newman's Own Foundation.

Owen Hughes

Owen Hughes has served on our Board of Directors since April 2013. He has served as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc., a biotechnology company, since February 2013. Prior to Intarcia, he served as a Director at Brookside Capital, a hedge fund under the Bain Capital umbrella, managing public and private healthcare investments from March 2008 to January 2013. Mr. Hughes has served as a Senior Portfolio Manager at Pyramis Global Advisors from 2006 to 2008, co-founder and partner at Triathlon Fund Management from 2003 to 2006, an Investment Associate at Ziff Brothers Investments from 2001 to 2003, and an Assistant Vice President at Morgan Stanley/Merrill Lynch from 1998 to 2001. Mr. Hughes is a director of Malin PLC. He earned a bachelor of arts from Dartmouth College. We believe Mr. Hughes is qualified to serve as a member of our Board of Directors because of his extensive business and professional experience, including his experience in the venture capital industry and years of analyzing development opportunities in the life sciences sector.

Tony Rosenberg

Anthony Rosenberg has served on our Board of Directors since March 2015. From January 2013 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis International, a pharmaceutical company. From March 2005 to December 2012, he served as Global Head of Business Development and Licensing at Novartis Pharmaceuticals. Prior to that, Mr. Rosenberg was Global Head of the Transplant and Immunology Business Unit at Novartis Pharmaceuticals from 2000 to 2005. Mr. Rosenberg initially joined Sandoz, a predecessor to Novartis, in 1980. Mr. Rosenberg served as a director of Idenix Pharmaceuticals, Inc. from June 2009 to March 2012 and from December 2012 to March 2013. Mr. Rosenberg holds a B.Sc from the University of Leicester and an M.Sc in physiology from the University of London. We believe Mr. Rosenberg is qualified to serve as a member of our Board of Directors due to his extensive experience in mergers and acquisitions and licensing in the pharmaceutical sector.

Debasish Roychowdhury, MD

Debasish Roychowdhury, MD is a medical oncologist with over 15 years of comprehensive pharmaceutical industry and senior management experience and over 14 years of patient care, academic research and teaching experience. Debasish is a leader in the pharmaceutical industry across multiple functional and cross-functional areas, regions and matrices, including – all stages of R&D, regulatory, commercial operations and medical affairs, market access, business development and alliance management. Debasish was involved in nine new drug approvals in US and EU and other markets and numerous supplemental approvals.

Debasish Roychowdhury is currently President of Nirvan Consultants, LLC and advises biotechnology companies and institutions. He was one of the founding members of the Seragon Clinical and Scientific Advisory Board and was the company's Chief Medical Officer where he played a key role in the development and advancement of Seragon's selective estrogen receptor degrader (SERD) platform for breast cancer and other hormone-driven cancers till the company was acquired by Roche in August 2014.

Prior to Seragon, Debasish was the Senior Vice President and Head of the Global Oncology Division at Sanofi till November 2013. Prior to that, he served as the Vice President for Clinical Development at GlaxoSmithKline and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. He is a member of the Board of Directors for Lytix Biopharma AS.

Robert E. Ward

Bob Ward joined Radius Health as president and chief executive officer in 2013. Bob has more than 25 years of experience in the biopharmaceutical industry on both the R&D and the business side of a number of leading companies. During his tenure, Radius Health has completed late stage development of its lead compound and filed the first global regulatory new drug applications, successfully raised over $750 million in private and public financings – including an initial public offering in 2014, and advanced other novel compounds/drug delivery technologies in clinical development. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca (AZ) focusing on areas outside of AZ's historical therapeutic focus, including orphan drugs and endocrinology. After starting his career in the Molecular Biology discovery group at Genentech, Mr. Ward progressed through a series of management and executive roles with established biopharmaceutical companies including NPS Pharmaceuticals, Schering-Plough (Merck), and Bristol-Myers Squibb. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara; an M.S. in Management from the New Jersey Institute of Technology; and an M.A. in Immunology from The Johns Hopkins University School of Medicine.

John Katzenellenbogen, PhD

Founder

John Katzenellenbogen, PhD is a Founder of Radius and is the Swanlund Professor of Chemistry at the University of Illinois at Urbana-Champaign. Dr. Katzenellenbogen's research is focused on aspects of the structure, function, and use of steroid receptors. He has prepared and evaluated receptor ligands having novel structures and activities and developed radiolabeled steroids for imaging receptor-positive tumors of the breast and prostate by positron emission tomography. More recently, Dr. Katzenellenbogen has initiated biochemical and biophysical studies on the dynamics of the estrogen receptors and their interaction with coregulator proteins. Dr. Katzenellenbogen is a Fellow of the American Academy of Arts and Sciences. He has given numerous named lecture presentations and received three NIH MERIT awards, the Paul C. Aebersold Award from the Society of Nuclear Medicine, and a Cope Scholar Award from the American Chemical Society. Dr. Katzenellenbogen conducted graduate studies with Professor E.J. Corey at Harvard University and received a PhD from Harvard University.

C. Richard Lyttle, PhD

Chairman, SAB

Dr. Lyttle has served as Chairman of the Radius Scientific Advisory Board since June 2012. He previously served as President and CEO of Radius from September 2004 to December 2011 and interim Chief Scientific Officer from December 2011 to June 2012. Dr. Lyttle served as Executive Chairman of Karos Pharmaceuticals from July 2010 to November 2013. Previously, he was Vice President of Discovery for Women's Health and Bone as well as Head of the Women's Health Research Institute at Wyeth. At Wyeth, he directed drug discovery in women's health for several areas including menopause, contraception, reproductive disorders, osteoarthritis, osteoporosis, and urinary incontinence. Under his leadership, Wyeth advanced 17 new product candidates into preclinical and clinical development, including the SERM, bazedoxifene; Tanaproget, a novel non-steroidal contraceptive; and DVS-233 for vasomotor symptoms associated with menopause. Prior to joining Wyeth, Dr. Lyttle was Research Professor of Obstetrics, Gynecology, and Pharmacology at the University of Pennsylvania. He received a PhD in Biochemistry from Queen's University, Kingston, Ontario, followed by postdoctoral research at the Population Council at the Rockefeller University, and the University of Chicago.

Stavros C. Manolagas, MD, PhD

Founder

Stavros Manolagas, MD, PhD, is a Founder of Radius and is Professor of Medicine and Director of the Division of Endocrinology and Metabolism, University of Arkansas for Medical Sciences (UAMS); Director of the UAMS/VA Center for Osteoporosis and Metabolic Bone Disease; and Chief of the Section of Endocrinology in the Central Arkansas Veterans Healthcare System. Dr. Manolagas's research interests include vitamin D metabolism; the interplay among hormones, cytokines, the hematopoietic/immune system and bone; cellular and molecular mechanisms of the pathogenesis of osteoporosis due to estrogen or androgen deficiency, old age, and glucocorticoid excess; mechanism of steroid hormone-receptor action; and the discovery of anabolic bone therapies. Previous positions include Professor of Medicine as well as Chief of the Section of Endocrinology and Metabolism in the Indianapolis VA Medical Center at Indiana University, and Associate Professor of Medicine in Residence at the University of California in San Diego. His honors and awards include the UAMS Dean's Distinguished Faculty Lecturer award, 2001; the inaugural Founders Award (Louis V. Avioli Award) of the American Society of Bone and Mineral Research, 2000; the 1999 AlliedSignal award for research on aging; and induction into the Association of American Physicians in 1996. Dr. Manolagas received an MD from the University of Athens Medical School and a PhD from the University of Manchester, England.

John T. Potts, MD, DSc

Founder

John Potts, MD, DSc, is a Founder of Radius and is the Jackson Distinguished Professor of Clinical Medicine at the Massachusetts General Hospital (MGH) and Harvard Medical School. An internationally recognized authority on calcium metabolism and the hormonal mechanisms that govern it, Dr. Potts has been a pioneer in the chemistry and biology of parathyroid hormone (PTH) and its role in clinical disorders of bone and mineral ion metabolism. His research interests focus on calcium and bone metabolism and PTH; his clinical work is on disorders of calcium metabolism and osteoporosis. Previously, Dr. Potts served as Director of Research, as Chairman of the Department of Medicine and Physician-in-Chief, and as Chief of the Endocrine Unit at MGH. Previous to that, he conducted research on protein chemistry at the National Institutes of Health with Nobel laureate Christian Anfinsen. His honors and awards include the Association of Professors of Medicine's Robert H. Williams, MD, Distinguished Chair of Medicine Award (2002); the Biomedical Science Career Program Hope Award (2001); the Endocrine Society's Fred Konrad Koch Award (1991); and the American Society for Bone and Mineral Research's William F. Neumann Award (1987). He holds active and honorary memberships in a number of scientific and professional organizations including the Institute of Medicine and the American Academy of Arts and Sciences and is an elected member of the National Academy of Sciences. He received an MD from the University of Pennsylvania.

Michael Rosenblatt, MD

Founder and Observer

Michael Rosenblatt was recently EVP and CMO for Merck until his retirement in 2016. Prior to joining Merck in 2009, he was Dean of Tufts University School of Medicine. Before that, he was the George R. Minot Professor of Medicine at Harvard Medical School 1998-2003. Dr. Rosenblatt has also served as Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center, Harvard faculty dean, senior vice president for Academic Programs at CareGroup and Beth Israel Deaconess Medical Center, and Director of the Harvard-MIT Division of Health Sciences and Technology. Previously, Dr. Rosenblatt was Senior Vice President of Research and Vice President of Biological Research for Merck.

Carlos Arteaga, MD

Carlos Arteaga, MD

Dr. Arteaga joined Vanderbilt University in 1989 where he now holds the Donna S. Hall Chair in Breast Cancer Research and serves as Professor of Medicine and Cancer Biology. He is Director of the Center for Cancer Targeted Therapies and the Breast Cancer Program of the Vanderbilt-Ingram Cancer Center (VICC) where he also serves as Associate Director for Translational/Clinical Research. He has over 300 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer.

He is a member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005). Arteaga is the recipient of the 2003 AACR Richard & Hinda Rosenthal Award, a 2007-2017 ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO), the 2011 Brinker Award for Scientific Distinction from the Susan G. Komen for the Cure Foundation, and the 2015 Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation. He was elected Fellow of the AACR Academy in 2015, and serves in the Scientific Advisory Board of the Komen Foundation. He has chaired the AACR Special Conference 'Advances in Breast Cancer Research' since 2003 and has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. In 2014, he served as President of the American Association for Cancer Research (AACR).

Mitch Dowsett, PhD, FMedSci

Mitch Dowsett, PhD, FMedSci

Mitch Dowsett, PhD, FMedSci, is a clinical scientist who has over 540 papers listed on PubMed. He is Head of the Academic Department of Biochemistry and of the Centre for Molecular Pathology at the Royal Marsden Hospital. He is Professor of Biochemical Endocrinology at the Institute of Cancer Research and of Translational Research in the Breakthrough Breast Cancer Centre in London, UK.

His major research interests involve hormonal aspects of breast cancer and the application of biomarkers in clinical trials. He was a major player in the development of aromatase inhibitors, now the most widely used endocrine agent for postmenopausal breast cancer patients and chairs the Aromatase Inhibitor Overview Group that co-ordinates the collaborative assessment of the merged data from the international trials. He is a member of the ASCO/CAP Steering Committees for guidelines on both HER2 and steroid receptors and he co-chairs the International Working Group on Ki67 in Breast Cancer. He was the founding chairman of the National Cancer Research Institute's Biomarker and Imaging Clinical Study Group.

Professor Dowsett is particularly interested in the evaluation of new and established agents in presurgical studies of breast cancer including being co-PI of the 4,450 patient POETIC trial, the largest study conducted to date. He sits on the Executive and/or Steering Committees of many international trials and served for 7 years on the Executive Committee of the Breast International Group (BIG).He has received the William L. McGuire Award and the Brinker Award for Scientific Distinction and has given multiple named lectures.

Martine J. Piccart, MD, PhD

Martine J. Piccart, MD, PhD

Martine J. Piccart, MD, PhD, is Professor of Oncology at the Université Libre de Bruxelles (ULB) and Director of Medicine at the Jules Bordet Institute, in Brussels, Belgium. Earning her medical degrees at the ULB and oncology qualifications in New York and London, she is also member of the Belgian Royal Academy of Medicine.

With a primary interest in breast cancer and drug development, Dr. Piccart is a leader in international research collaboration and is the principal or co-principal investigator of many clinical trials, including HERA, MINDACT and ALTTO. She is co-founder and chair of the Breast International Group (BIG), uniting 47 academic research groups from around the world and running over 30 trials under its umbrella. BIG's research programs include the European Commission supported TRANSBIG consortium of 29 institutions in 11 countries (running with the EORTC the MINDACT trial) and NeoBIG, an innovative biomarker and drug development program focused on neo-adjuvant trials.

Dr. Piccart is active in numerous professional organizations. She is Past-President of the EORTC and ESMO, served on the ASCO Board and is now President of ECCO.

(Co) author of more than 390 publications in peer-reviewed journals, she has received numerous prestigious awards for her research contributions including the Jill Rose Award (New York) and the William L. McGuire Award (San Antonio), and the David Karnovsky Award (Chicago).

George W. Sledge, Jr., MD

George W. Sledge, Jr., MD

George W. Sledge Jr., MD, is Professor and Chief of Medical Oncology at Stanford University Medical Center, as of January 2013. Dr. George Sledge was most recently co-¬‐director of the breast cancer program at the Indiana University Cancer Center, where he is was a Professor of Medicine and Pathology at the Indiana University Simon Cancer Center. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer. He has published over 280 articles in medical journals about breast cancer and chaired several nationwide clinical trials involving new breast cancer treatments. His work spans both laboratory and clinic.

Dr Sledge serves as Editor‐in-Chief of the journal Clinical Breast Cancer, and is Past President of the American Society of Clinical Oncology. He served as chairman of the Breast Committee of the Eastern Cooperative Oncology Group from 2002 – 2009, where he played an important role in the development of several nationwide clinical trials. He has also served as chair of ASCO's Education Committee, as a member of the Department of Defense Breast Cancer Research Program's Integration Panel, as a member of the Food and Drug Administration's Oncology Drug Advisory Committee (ODAC), and currently as a member of the External Advisory Committee for The Cancer Genome Atlas (TCGA) project.

Dr. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of 'Excellence for Medicine'. Dr. Sledge was also the recipient of the 2006 Komen Foundation Brinker Award for Scientific Distinction, the 2007 Breast Cancer Research Foundation's Jill Rose Award and was the 2010 recipient of the William L. McGuire Award from the San Antonio Breast Cancer Symposium.